All In Biotech

NDA 212489 · Amneal

Ongentys

Opicapone · Oral · Catechol-O-Methyltransferase Inhibitor

Novel

Last checked: Nov 19, 2026Latest source record: Oct 10, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2020

Apr 24, 2020

Approved uses

1

Original approval plus efficacy supplements

Registered trials

46

4 Phase 3, 0 recruiting

FAERS reports

2,446

1,874 serious, 250 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Nov 4, 2025.

ONGENTYS is indicated as adjunctive treatment to levodopa/carbidopa in patients with Parkinson’s disease (PD) experiencing “off” episodes. ONGENTYS is a catechol-O-methyltransferase (COMT) inhibitor indicated as adjunctive treatment to levodopa/carbidopa in patients with Parkinson’s disease (PD) experiencing “off” episodes. ( 1 )

Mechanism: Opicapone is a selective and reversible inhibitor of catechol-O-methyltransferase (COMT). COMT catalyzes the transfer of the methyl group of S-adenosyl-L-methionine to the phenolic group of substrates that contain a catechol structure. Physiological substrates of COMT include DOPA, catecholamines (dopamine, norepinephrine, and epinephrine), and their hydroxylated metabolites. When decarboxylation of levodopa is prevented by carbidopa, COMT becomes the major metabolizing enzyme for levodopa, catalyzing its metabolism to 3-methoxy-4-hydroxy-L-phenylalanine (3-OMD).

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Apr 24, 2020 Original approval · Type 1 - New Molecular Entity NovelLabelLetterReview
2 products under this application
  • ONGENTYS · OPICAPONE 50MG · CAPSULE, ORAL · Prescription
  • ONGENTYS · OPICAPONE 25MG · CAPSULE, ORAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Opicapone" as an intervention, any sponsor and status, largest first.

All 46 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • hallucination339
  • dyskinesia338
  • fall291
  • on and off phenomenon196
  • tremor163
  • death150
  • gait disturbance143
  • drug ineffective134
  • confusional state130
  • parkinson^s disease127
  • fatigue119
  • hallucination, visual116

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20161
201721
201840
201961
2020177
2021567
2022277
2023243
2024258
2025358
2026443

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Ongentys (Opicapone)

2024 spending

$15.4M

Beneficiaries

3,276

16,686 claims

Per beneficiary

$4,687

$21.75 per unit

View as table
YearSpending
2020$545,253
2021$6,710,087
2022$11,855,741
2023$15,941,380
2024$15,354,274

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 38 on PubMed

Sponsor: Amneal

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.